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Background: Germline knockout mice are invaluable in understanding the function of
the targeted genes. Sometimes, however, unexpected phenotypes are encountered,
due in part to the activation of compensatory mechanisms. Germline ablation of
cardiac myosin light chain kinase (cMLCK) causes mild cardiac dysfunction with
cardiomyocyte hypertrophy, whereas ablation in adult hearts results in acute heart
failure with cardiomyocyte atrophy. We hypothesized that compensation after ablation of
cMLCK is dependent on developmental staging and perinatal-onset of cMLCK ablation
will result in more evident heart failure than germline ablation, but less profound when
compared to adult-onset ablation.
Methods and Results: The floxed-Mylk3 gene was ablated at the beginning of the
perinatal stage using a single intra-peritoneal tamoxifen injection of 50 mg/kg into
pregnant mice on the 19th day of gestation, this being the final day of gestation. The
level of cMLCK protein level could no longer be detected 3 days after the injection,
with these mice hereafter denoted as the perinatal Mylk3-KO. At postnatal day 19,
shortly before weaning age, these mice showed reduced cardiac contractility with a
fractional shortening 22.8 ± 1.0% (n = 7) as opposed to 31.4 ± 1.0% (n = 11) in
controls. The ratio of the heart weight relative to body weight was significantly increased
at 6.68 ± 0.28mg/g (n = 12) relative to the two control groups, 5.90 ± 0.16 (flox/flox,
n = 11) and 5.81 ± 0.33 (wild/wild/Cre, n = 5), accompanied by reduced body weight.
Furthermore, their cardiomyocytes were elongated without thickening, with a long-axis
of 101.8 ± 2.4µm (n = 320) as opposed to 87.1 ± 1.6µm (n = 360) in the controls.
Conclusion: Perinatal ablation of cMLCK produces an increase of heart weight/body
weight ratio, a reduction of contractility, and an increase in the expression of fetal genes.
The perinatal Mylk3-KO cardiomyocytes were elongated in the absence of thickening,
differing from the compensatory hypertrophy shown in the germline knockout, and the
cardomyocyte thinning shown in adult-inducible knockout.
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INTRODUCTION
The incidence of congestive heart failure in childhood ranges
from 2.95 to 23.2 in each 1000 patients, of which just over
80% have congenital heart disease, followed by the population
with cardiomyopathies (7%) and arrhythmias (2%) (Schmaltz,
2015). The signs and symptoms of heart failure include growth
retardation, respiratory distress, and exercise intolerance. The
failure in the volume-overloaded heart occurs in the setting of
left-to-right shunts, such as ventricular septal defects, persistent
patency of the arterial duct, or atrioventricular septal defects.
On the other hand, aortic stenosis is the most common cause
of pressure-overload heart failure. Complex malformations can
induce both volume- and pressure-overloaded heart failure (Hsu
and Pearson, 2009a,b; Schmaltz, 2015). As in adult patients, the
brain natriuretic peptide (BNP)/N-terminal prohormone BNP
is used as a biomarker heart failure in childhood, despite the
knowledge that there is an age-dependent variation in normal
individuals from∼3000 pg/ml in 0–2 days of age, which drops to
∼100 pg/ml between 1 month and 1-year of age (Nir et al., 2009;
Schmaltz, 2015).
In clinical settings, a reduction in phosphorylation of myosin
light chain 2 (MLC2) has been demonstrated in adult patients
with heart failure (Sanbe et al., 1999; Davis et al., 2001; Moss and
Fitzsimons, 2006; Stelzer et al., 2006; Scruggs and Solaro, 2011;
Sheikh et al., 2012, 2014). It is not yet known, to the best of our
knowledge, whether phosphorylation of MLC2, or its responsive
kinase, cardiac myosin light chain kinase (cMLCK), is reduced
in children with heart failure. When, in genetically modified
mice, cMLCK encoded by Mylk3 gene, was ablated either from
the germline or inducibly in adulthood, both populations of
cMLCK-deficient mice exhibited heart failure (Warren et al.,
2012; Massengill et al., 2016). Knockout in the germline, however,
leads to compensatory cardiac hypertrophy, while induction of
the knockout in adult mice results in cardiomyocyte atrophy.
These studies showed the potential that embryonic hearts have
a higher ability to adapt in the absence of cMLCK compared
to adult hearts. In this study, we queried if cMLCK ablation
during the perinatal stage leads to an intermediate phenotype
between those encountered in the setting of embryonic- or adult-
onset ablation. We found that perinatal knockout, beginning at
embryonic day 19, did indeed produce mice exhibiting moderate
heart failure accompanied by elongated cardiomyocytes, but in
the absence of any hypertrophy.
METHODS
Mouse Models
A conditional null allele of Mylk3 was generated by introducing
loxP sites spanning exon 5, which was done through homologous
recombination in ES cells as described previously (Warren
et al., 2012). Floxed-Mylk3 homozygous mice (Mylk3flox/flox)
(Massengill et al., 2016) were bred with transgenic mice carrying
the Cre-ERTM gene under CMV promoter, Tg(CAGGS-Cre-
ERTM) (Hayashi and McMahon, 2002). Subsequent matings
between offspring generatedMylk3flox/flox/Tg-CAGGS-Cre-ERTM,
Mylk3wild/wild/Tg-CAGGS-Cre-ERTM, and Mylk3flox/flox on a
mixed genetic background, mainly C57BL/6J. For perinatal
deletion of the floxed-Mylk3 genes, a single injection of tamoxifen
at 50mg/kg body weight, was administered intra-peritoneally
to pregnant mice on the 19th day of gestation, which is the
final day of gestation in the mouse. All animal experiments
were performed using protocols reviewed and approved by
the University of Florida Institutional Animal Care and Use
Committee.
Echocardiogram
Mice were anesthetized with 1.5–2% isoflurane for M-mode
ultrasound imaging of the left ventricles using Vevo700 as
described previously (Briggs et al., 2008; Takeda et al., 2009;
Warren et al., 2012; Massengill et al., 2016).
Measurements of Cardiomyocyte Size
Cardiomyocytes were isolated by retrograde perfusion of
collagenase as described previously (Takeda et al., 2009; Warren
et al., 2012; Massengill et al., 2016). Briefly, the hearts were
perfused by Langendorff system with the collagenase digestion
buffer (type 2 collagenase 2mg/ml, in MEM with 10mM taurine,
3.8mM creatine, 30mM 2,3-Butanedione 2-Monoxime, and 20
units of insulin, pH 7.3) at 37◦C for 30min. Then the hearts were
minced into 8–10 pieces, and further digested with the second
collagenase digestion (type 2 collagenase 2mg/ml, in MEM with
10mM taurine, 3.8mM creatine, 30mM 2,3-Butanedione 2-
Monoxime, 20 units of insulin, 0.5% bovine serum albumin,
and 0.3mM CaCl2, pH 7.3) at 37
◦C for 10 min. The cells were
spun down at 46 × g for 2min, resuspended in the second
digestion buffer without collagenase and loaded onto a 36%
Percoll gradient (GE Healthcare). After centrifugation at 290 ×
g for 10min, cardiomyocytes were pelleted and non-myocytes
were floated on top. The cardiomyocytes were washed twice
with the second digestion buffer without collagenase, suspended
and plated on the laminin-coated coverglass for 15min. The
cells were immediately fixed with 4% PFA and analyzed for
measurement of cell size as described previously (Takeda et al.,
2009; Warren et al., 2012; Massengill et al., 2016). All the reagents
except for Percoll were obtained from Sigma.
Western Blotting and Histological Analyses
Western blot analyses and immunostaining were performed with
GAPDH (MAB374, EMDMillipore), phospho-MLC2v (gift from
Dr. N. Epstein, NIH) (Davis et al., 2001), MLC2 (F109/3E1. ALX-
BC-1150-S-L005, Enzo Life Science), and cMLCK (Chan et al.,
2008) antibodies. The rabbit affinity-purified cMLCK antibody
production has been described previously (Chan et al., 2008).
Briefly, the antigen was purified from GST-cMLCK(aa 28-463)
following cleavage of GST-tag using thrombin and SDS-PAGE
separation followed by electro-elution. Rabbits were injected
with the antigen and adjuvants 4 times, and the serum from
these animals were affinity-purified using GST-cMLCK(aa 28-
463) covalently-coupled beads. 1:4000-diluted antibody was used
for Western blotting.
Histological sections (5µm) were analyzed by hemotoxylin
and eosin staining, as well as for fibrosis after Picrosirius red
staining, which was performed by heating the tissue sections at
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60◦C for 45 min before deparaffinization and then immersing
them in a combination of 0.1% direct red 80 and 0.1% fast green
FCF in 1.2% picric acid for 1 h. TUNEL staining was performed
using the In Situ Cell Death Detection Kit (Roche 11684795910).
Real-Time RT-PCR
Real-time RT-PCR was performed using inventoried Taqman
Gene Expression Assays (Thermo Fisher Scientific): Atrial
natriuretic factor (ANF) Mm01255748, brain natriuretic peptide
FIGURE 1 | Experimental design of perinatal inducible Mylk3-KO mice leading to acute heart failure. (A) Strategy for cardiac tamoxifen-inducible perinatal
Mylk3-KO. (B) Timeline of experiments. (C) Western blotting demonstrates the expression of cMLCK and MLC2 phosphorylation 3 days after tamoxifen-injection
in Mylk3flox/flox with or without the CAGGS-Cre-ERTM transgene. (D) Heart weight/body weight (HW/BW) ratio, body weight (BW), and heart weight (HW) of
Mylk3flox/flox/Tg-CAGGS-Cre-ERTM compared to two controls, Mylk3flox/flox and Mylk3wild/wild/Tg-CAGGS-Cre-ERTM. (E) Representative sagittal sections of the
heart between control (Cre-) and Mylk3 KO (Cre +) at P19. Bar = 1mm. (F) Real-time RT-PCR shows fold differences in mRNA of ANF, BNP, and β-MHC relative to
β-actin with the value in Mylk3flox/flox defined as 1 (mean ± SE). *p < 0.05 using ANOVA for Panel (D) and T-test for Panel (F).
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(BNP) Mm00435304, and β-myosin heavy chain (βMHC)
Mm00600555. All were normalized to β-actin expression (No.
4352933E). Duplicated experiments were averaged.
Statistical Analyses
Data presented are expressed as mean values ± S.E.M. Results
were compared usingT-test or ANOVAwith Fisher’s post-hoc test
(SPSS version 24). p < 0.05 was considered significant.
RESULTS
There is an Increase of Heart Weight
Relative to the Body Weight, and Overall
Weight Loss in Perinatal Mylk3-KO Mice
To examine the effects of cMLCK in perinatal cardiac function,
we generated tamoxifen-inducible Mylk3 knockout mice that
carry homozygous floxed-Mylk3 alleles and heterozygous Cre-
ERTM transgene under the control of the CMV enhancer and the
chicken β-globulin promoter (CAGGS-Cre-ERTM) (Figure 1A).
Deletion of floxed-exon 5 resulted in elimination of the first
coding exon of the catalytic domain, and a frame-shift of the
subsequent downstream exons. In addition, deletion of exon 5
resulted in reduction of cMLCK mRNA (Warren et al., 2012),
attributable to a non-sense-mediated mRNA decay (Conti and
Izaurralde, 2005), with targeted cMLCK mRNA containing a
premature termination codon. Hereafter, conditional deletion
of Mylk3 gene in Mylk3flox/flox/CAGGS-Cre-ERTM mice with
tamoxifen injection at embryonic day 19, will be described as
perinatal Mylk3-KO. Of note, this model produces a general
knockout of the Mylk3 gene, although the expression of cMLCK
is known to be restricted to the myocardium (Chan et al.,
2008).
A single tamoxifen injection into pregnant mice on gestational
day 19, at 50mg/kg, given intraperitoneally, reduced the
expression of cMLCK protein and MLC2 phosphorylation by
postnatal day 3 (P3), such that it could no longer be detected
(Figures 1B,C). During the initial experiment, we noticed that
perinatal Mylk3-KO mice appeared unhealthy with growth
retardation on P19, 2 days before weaning, and there was concern
that these mice would die after weaning. Indeed, the ratio of heart
weight/body weight (HW/BW) was increased in the perinatal
Mylk3-KOmice compared to the two control groups, represented
by the Mylk3flox/flox and Mylk3wild/wild/Tg-CAGGS-Cre-ERTM
mice, mainly due to a decrease in body weight (Figure 1D).
The remaining groups of mice, therefore, were analyzed
using the same experimental timeline. In Figure 1E, we show
representative hearts dissected from the control and perinatal
Mylk3-KO mice. Expression of fetal genes, often observed
in failing hearts, was increased in perinatal Mylk3-KO mice,
including atrial natriuretic factor (ANF), BNP, and β-myosin
FIGURE 2 | Reduced contractility and elongation of cardiomyocytes in perinatal Mylk3-KO mice. (A) Representative echocardiographic images, and (B)
Summary of echocardiographic indices of inducible Mylk3-KO mice and control at P19. (C) Representative images of isolated cardiomyocytes, and (D) summarized
data of short- and long axis and cell area size at P19. mean ± SE. *p < 0.05 using T-test. FS, fractional shortening; ED, end-diastolic; ES, end-systolic; PW, posterior
wall.
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heavy chain (βMHC) (Figure 1F). These results indicate that
the perinatal Mylk3-KO induced heart failure, as shown by the
increase of HW/BW ratio, increased fetal gene expression, and
the loss of body weight as compared to the controls.
Contractile Dysfunction and
Cardiomyocyte Elongation in the Perinatal
Mylk3-KO Mice
Echocardiography performed on the 19th postnatal day
demonstrated a significant reduction in cardiac contractility in
perinatalMylk3-KOmice, as measured by %fractional shortening
(%FS), and increased systolic dimensions of the left ventricular
cavity (Figures 2A,B). Cardiomyocytes isolated from these mice
were significantly longer than their controls, albeit without
any change in the diameter of the short-axis (Figures 2C,D).
Histological analyses, however, failed to show any interstitial
fibrosis, nor an increase in TUNEL-positive cells (Figures 3A,B).
Comparison of the Germline, Perinatal, and
Adult-Inducible Knockout Models
Together with our previous studies (Warren et al., 2012;
Massengill et al., 2016), we have now analyzed three different
Mylk3 knockout mouse models under similar experimental
conditions, with the knockout induced in the germline, in
the perinatal period, or at adulthood. The populations show
both phenotypic similarities and differences, as we have
summarized in Table 1. All three models demonstrate a
reduction in cardiac contractility, accompanied with elongation
of the cardiomyocytes. On the other hand, the findings
regarding the fetal gene expression, interstitial fibrosis, and
thickening of the cardiomyocytes were different in the three
models. When the knockout was introduced in the germline, it
failed to induce expression of fetal genes and interstitial fibrosis,
but the cardiomyocytes demonstrated thickening. Knockout in
the perinatal period, in contrast, did produce an increase in the
expression of fetal genes, but again in the absence of fibrosis,
and without producing any change in the short-axis dimensions
of cardiomyocytes. Knockout in adult mice produced expression
of fetal genes, fibrosis, and cardiomyocyte atrophy. These results
showed that, when theMylk3 gene is eliminated in early stages of
development, it is most effectively compensated. Compensation,
in contrast, is ineffective when the Mylk3 gene is knocked-
out in adult mice. Notably, we included two controls in the
inducible knockout studies, namely flox/flox and wild/wild/Cre
mice with tamoxifen injection in the present and previous studies
(Massengill et al., 2016), so as to eliminate any effects of the
potential toxicity of tamoxifen and/or Cre transgene for cardiac
contractility. Neither of the control populations showed any
significant differences in HW/BW ratio or cardiac contractility.
DISCUSSION
We have now shown that elimination of cMLCK in mice
in the perinatal period results in an increase of heart
weight/body weight ratio with decreased body weight, reduction
of contractility accompanied by elongated cardiomyocytes, and
FIGURE 3 | No apparent interstitial fibrosis or increase of
TUNEL-positive cells in perinatal Mylk3-KO mice. (A) Representative
H&E- and Picrosirius red-stained heart sections from control and perinatal
Mylk3-KO mice. No apparent fibrosis were seen in inducible marked with
arrowheads. (B) Representative TUNEL-staining, and the quantitative
TUNEL-positive cells indicated by arrows relative to the area size scanned per
mouse heart (per mm2). Total area size examined, Mylk3flox/flox , 18.1mm2
from 4 mice; Mylk3flox/flox/Cre, 12.3mm2 from 3 mice. Data presented are
expressed as mean values ± S.E.
an increase in the expression of fetal genes. Under sustained
pressure overload, adaptive cardiomyocyte hypertrophy transits
to maladaptive elongation of cardiomyocytes, and persistent
reductions in contractile force. Such cardiac remodeling is
thought to involve an initial adaptive addition of sarcomeres in
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TABLE 1 | Summary of the phenotypes displayed in three Mylk3 knockout models.
Mylk3 knockout Age Duration of absence Fetal Contractility Fibrosis Long Short TUNEL
types analyzed of cMLCK gene axis axis
Germline 3 month >3 months No change Reduced No Elongated Thickened N/A
Perinatal P19 16–19 days Increased Reduced No Elongated No change No change
Adult 10–12 weeks 4–5 days or 11–12 days Increased Reduced Yes Elongated Thinned Increased
parallel, thus thickening the cardiomyocytes, and a subsequent
addition of sarcomere in series to produce elongatation (Diwan
and Dorn, 2007; Balasubramanian et al., 2009; Russell et al., 2010;
Rosca et al., 2013).
In adult cardiomyocytes, with their semi-crystalline
architecture, and under the continuous production of myocardial
force, the exact processes of cardiac remodeling remain
unknown. In adult mice, nonetheless, expression of cMLCK
has been shown to be reduced after pressure overload by ∼80%
within 1 week. This effect persists, coinciding with the transition
from compensated to decompensated hypertrophic heart failure
(Warren et al., 2012). Furthermore, our recent study showed that
elimination of cMLCK in adult mice with age of 10–12 weeks led
to acute heart failure accompanied by cardiomyocyte atrophy
with elongated and thinner cardiomyocytes within 1 week after
tamoxifen injection. The heart failure persisted with slight
further progression in cardiac contractility demonstrated in
echocardiogram 2 weeks after tamoxifen injection. Furthermore,
adultMylk3-KOmice knockoutmice fail to demonstrate adaptive
pressure overloaded cardiomyocyte thickening (Massengill et al.,
2016).
We could not examine the effects of pressure overload in
neonatal hearts, such as seen in aortic stenosis in children,
due to technical burdens. To best of our knowledge, it is
unknown whether heart failure as seen in childhood also involves
reduction of phosphorylation of MLC and cMLCK. We noted,
nonetheless, that 19 days after tamoxifen injection into perinatal
Mylk3-KO mice, there was a heart failure with increase of the
heart weight/body weight ratio, reduction of contractility with
increase of both systolic and diastolic left ventricular cavity with
elongation but without thinning of cardiomyocytes, and increase
of fetal gene expression compared to controls. We cannot explain
why the heart weight was not increased despite the increase
of surface area size and elongation of cardiomyocytes, but it
might be possible that individual cardiomyocytes from perinatal
Mylk3-KOmice are less heavy than those from controls.
In the perinatal Mylk3-KO mice, we were unable to detect
interstitial fibrosis in the ventricles. We have previously
analyzed mice with perinatal knockout of transcription factor,
Nkx2-5, using floxed-Nkx2-5 mice. Nkx2-5 regulates multiple
downstream targets including cMLCK (Chan et al., 2008),
and perinatal Nkx2-5-KO mice demonstrate more profound
heart failure compared to perinatal Mylk3-KO mice, with a
1.44 fold increase of HW/BW ratio at P12 (Briggs et al.,
2008). The perinatal Nkx2-5 knockout mice did not show any
apparent interstitial fibrosis (Briggs et al., 2008). To best of our
knowledge, there are no additional reports describing genetically-
induced perinatal models of heart failure in mice. Absence
of fibrosis, however, has also been observed in neonatal mice
following cardiac injury, such as myocardial infarction or partial
ventricular resection, partly due to cardiomyocyte regeneration
persisting in neonatal hearts within a few days after birth,
and difference in extracellular matrix composition and immune
responses (Porrello and Olson, 2014).
In mice, cMLCK is expressed from an early embryonic stage,
at least beyond E10.5, and is restricted to the hearts when
examined in major organs using Northern blotting (Chan et al.,
2008). Because of this, we presume that the reduction in body
weight observed in the perinatal Mylk3-KO mice is due to heart
failure, but we cannot rule out the possibility that cMLCK
may directly regulate body weight by unknown mechanisms.
Additional experiments are now needed further to address and
explore the mechanisms underscoring the growth retardation
noted in these mice.
To mitigate the possibility that a high dose of tamoxifen,
such as 80mg/kg/day given over 5 days, would result in heart
failure (Koitabashi et al., 2009), we utilized a substantially lower
dose of tamoxifen, namely 50 mg/kg/day given but once. We
also included control wildtype mice with CAGGS-Cre-ERTM
mice, which showed no change in HW/BW ratio compared to
another control, flox/flox mice, after tamoxifen injection, thus
eliminating the possibility that the heart failure was due to
presence of the CAGGS-Cre-ERTM transgene.
We recognize the limitations in our current study. The
mechanisms underlying the loss of cMLCK leading to
cardiomyocyte elongation are currently unknown, and future
experiments are required to elucidate these processes. We have
not examined perinatalMylk3-KO beyond 19 days of age because
these mice were noted to be unhealthy for weaning on day
21. The remodeling and functional differences between the
germline and perinatal Mylk3-KO models may be due to the
developmental age studied. Further experiments comparing
remodeling and cardiac function in these two knockout models
at the same ages, therefore, are highly desirable. Based on the
profound heart failure seen in adult-inducible Mylk3-KO mice,
nonetheless, we speculate that their cardiac function is unlikely
to improve in later life.
In summary, we have demonstrated that the cMLCK plays
essential roles in cardiac function during the perinatal period.
Our experiments point to the need for further clinical studies
in children with heart failure, exploring the phosphorylation of
MLC and reduction of cMLCK.
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